The key actions needed to end AIDS are relatively clear. The question is whether every government, funder, and implementing organisations will apply them.
Academic rigor, journalistic flair
Articles on HIV response
Displaying all articles
The high cost of pharmaceuticals often means only the richest patients get lifesaving medicines. As coronavirus drugs emerge, it will require hard, creative work to ensure they’re available to all.
The HIV epidemic is far from over and it’s not time to disengage, says International Aids Society President Linda-Gail Bekker.
Top contributors
-
Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town
-
Professor of Philosophy, Binghamton University, State University of New York
-
Honorary Research Associate, Centre for Infectious Disease Epidemiology and Research, University of Cape Town
